Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;4(7):587-595.
doi: 10.1002/acr2.11432. Epub 2022 Apr 10.

Time-Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk

Affiliations

Time-Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk

Kazuki Yoshida et al. ACR Open Rheumatol. 2022 Jul.

Abstract

Objective: It is unknown how the relationship between disease activity in rheumatoid arthritis (RA) and cardiovascular (CV) events may change over time. We examined the potentially time-varying association of RA disease activity to CV events.

Methods: We used the CorEvitas prevalent RA registry. The Clinical Disease Activity Index (CDAI) score category, averaged within each 6-month window since enrollment, was the exposure, and the outcome was major adverse CV events (MACEs). We used marginal structural models to estimate the hazard ratio (HR), comparing each CDAI score category with remission, allowing for differential association over time. We predicted MACE-free survival under several CDAI score scenarios.

Results: We found 44,816 eligible patients (77% female; mean age 58 years) with a crude event rate of 5.3/1000 person-years (median follow-up 3.4 years). The strongest association between higher CDAI score and MACEs was observed during the first 6 months of enrollment (HR for CDAI score low 2.29 [95% CI: 1.21-4.36], moderate 2.81 [95% CI: 1.46-5.43], and high 2.99 [95% CI: 1.48-6.02]). These estimates gradually diminished; by year 5, the HRs were 1.00 (95% CI: 0.49-2.05) for low, 1.18 (95% CI: 0.51-2.71) for moderate, and 1.04 (95% CI: 0.45-2.40) for high CDAI score. Predicted MACE-free survival suggested a potential decrease in MACEs with a hypothetical earlier transition to remission.

Conclusion: The association of higher disease activity with CV events may be stronger earlier in the disease course of RA. Interventional studies may be warranted to precisely determine the effect of disease activity suppression on CV events in RA.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time‐varying hazard ratio estimates for MACEs associated with each CDAI score level compared with remission for each 6‐month interval. See Supplementary Figure 2 for a non‐superimposed version. The Y axis is on the log HR scale with the ticks at representative HR values. CDAI, Clinical Disease Activity Index for rheumatoid arthritis; HR, hazard ratio; MACE, major cardiovascular event.
Figure 2
Figure 2
Predicted MACE‐free survival under hypothetical sustained CDAI score levels based on time‐varying hazard ratio estimates from the final model (estimates in Figure 1). CDAI, Clinical Disease Activity Index for rheumatoid arthritis; MACE, major adverse cardiovascular event.
Figure 3
Figure 3
Predicted MACE‐free survival under hypothetical transition to sustained remission at 24 months and 6 months in comparison to hypothetical scenarios of having always‐remission‐level CDAI score (top curve: best‐case scenario) and having always high CDAI score (bottom curve: worst‐case scenario). A hypothetical transition to sustained remission at 24 months (left panel; middle three curves) was predicted to carry less dramatic CV benefit compared with transition to sustained remission at 6 months (right panel; middle three curves), which gave predicted MACE‐free survival curves fairly close to the hypothetical scenario of having always‐remission‐level CDAI score (top curve: best‐case scenario). CDAI, Clinical Disease Activity Index for rheumatoid arthritis; CV, cardiovascular; MACE, major adverse cardiovascular event.

References

    1. Monson RR, Hall AP. Mortality among arthritics. J Chronic Dis 1976;29:459–67. - PubMed
    1. Prasad M, Hermann J, Gabriel SE, Weyand CM, Mulvagh S, Mankad R, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 2015;12:168–76. - PMC - PubMed
    1. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009;61:1571–9. - PubMed
    1. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp‐Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011;70:929–34. - PubMed
    1. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45. - PubMed